Leaflet REOPRO 2mg / ml solution for injection / infusion
Indicated for: prevention of thrombotic complications in coronary interventions
Route of administration: injectable / infusion
Substance: abciximab (antiplatelet agent)
ATC: B01AC13 (Blood and blood forming organs | Antithrombotic agents | Platelet aggregation inhibitors excl. heparin)
Risk of severe allergic reaction. Seek urgent medical help if serious symptoms occur.
This medicine may have important interactions with other medicines.
This medicine is subject to additional monitoring.
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
This medicine may increase the risk of bleeding.
Abciximab is a medication used to prevent thrombotic complications during interventional cardiac procedures, such as coronary angioplasty. It is a glycoprotein IIb/IIIa receptor inhibitor that prevents platelet aggregation and blood clot formation.
This medication is administered intravenously and is primarily used in patients with acute coronary syndromes or those undergoing percutaneous coronary intervention (PCI). Abciximab is often combined with other antithrombotic agents, such as heparin or aspirin, to enhance treatment efficacy.
Side effects may include bleeding, thrombocytopenia (low platelet count), or allergic reactions. Therefore, patients must be closely monitored during administration. Its use is contraindicated in patients with a high risk of bleeding or a history of hemorrhagic stroke.
Abciximab is an effective medication for reducing the risk of thrombotic complications, but its use requires strict medical supervision.
General data about REOPRO 2mg / ml
- Substance: abciximab
- Date of latest medicines list: 01-12-2017
- Product code: W08065001
- Concentration: 2mg / ml
- Pharmaceutical form: solution for injection / infusion
- Quantity: 1
- Product type: Original
- Prescription status: S - Medicines dispensed with a restricted medical prescription, reserved for use in certain specialized fields.